Atreca Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Atreca stock.
View analyst ratings for Atreca or view top-rated stocks.

Wall Street analysts have given Atreca a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Atreca wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Atreca is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Atreca.

Atreca, Inc. (NASDAQ:BCEL) released its earnings results on Thursday, February, 25th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.02.
View Atreca's earnings history.

Atreca's stock was trading at $17.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BCEL stock has decreased by 32.0% and is now trading at $11.98.
View which stocks have been most impacted by COVID-19.

4 brokerages have issued 12 month price objectives for Atreca's shares. Their forecasts range from $25.00 to $33.00. On average, they anticipate Atreca's share price to reach $29.33 in the next twelve months. This suggests a possible upside of 144.9% from the stock's current price.
View analysts' price targets for Atreca or view top-rated stocks among Wall Street analysts.

2 employees have rated Atreca CEO John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among Atreca's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Atreca include Ironwood Pharmaceuticals (IRWD), Prelude Therapeutics (PRLD), Amneal Pharmaceuticals (AMRX), ADC Therapeutics (ADCT), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Aurinia Pharmaceuticals (AUPH), Harmony Biosciences (HRMY), ImmunoGen (IMGN), PMV Pharmaceuticals (PMVP), Arcutis Biotherapeutics (ARQT), Applied Molecular Transport (AMTI), Travere Therapeutics (TVTX), uniQure (QURE) and DiaMedica Therapeutics (DMCAF).
View all of BCEL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Homology Medicines (FIXX), Akero Therapeutics (AKRO), Hookipa Pharma (HOOK), Lumentum (LITE), TCR2 Therapeutics (TCRR) and Precision BioSciences (DTIL).

(BCEL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

Atreca trades on the NASDAQ under the ticker symbol "BCEL."

Atreca's stock is owned by many different institutional and retail investors. Top institutional shareholders include Mcdonald Partners LLC (0.06%). Company insiders that own Atreca stock include Guy Cavet, John A Orwin, Norman Michael Greenberg, Tito Serafini and William Hewitt Robinson.
View institutional ownership trends for Atreca.

BCEL stock was sold by a variety of institutional investors in the last quarter, including Mcdonald Partners LLC. Company insiders that have sold Atreca company stock in the last year include Norman Michael Greenberg, Tito Serafini, and William Hewitt Robinson.
View insider buying and selling activity for Atreca or view top insider-selling stocks.

Shares of BCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCEL stock can currently be purchased for approximately $11.98.

Atreca has a market capitalization of $441.24 million. The company earns $-67,480,000.00 in net income (profit) each year or ($4.26) on an earnings per share basis.

Atreca employs 130 workers across the globe.

The official website for Atreca is www.atreca.com.

Atreca is headquartered at 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063.

Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-595-2595 or via email at [email protected]